<div id="readability-page-1"><p>Ameritas Advisory Services LLC acquired a new position in shares of  Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 34,270 shares of the biotechnology company's stock, valued at approximately $1,502,000.</p><ul><li>Exelixis Reports Solid Earnings—Are New Highs Back on the Table?</li></ul><p>A number of other hedge funds have also recently bought and sold shares of the company. Farallon Capital Management LLC raised its position in  Exelixis by 21.6% in the 3rd quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company's stock worth $805,412,000 after buying an additional 3,466,000 shares during the last quarter.  Assetmark Inc. raised its position in  Exelixis by 1,230.8% in the 3rd quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company's stock worth $131,994,000 after buying an additional 2,955,813 shares during the last quarter.  AQR Capital Management LLC raised its position in  Exelixis by 20.7% in the 3rd quarter. AQR Capital Management LLC now owns 9,181,359 shares of the biotechnology company's stock worth $379,190,000 after buying an additional 1,575,280 shares during the last quarter.  Allianz Asset Management GmbH raised its position in  Exelixis by 153.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company's stock worth $101,720,000 after buying an additional 1,490,520 shares during the last quarter.  Finally, UBS Group AG raised its position in  Exelixis by 100.1% in the 3rd quarter. UBS Group AG now owns 2,655,069 shares of the biotechnology company's stock worth $109,654,000 after buying an additional 1,328,087 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors. </p><h2>Exelixis Price Performance</h2><p>EXEL stock opened at $51.10 on Friday. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $51.63. The company has a market capitalization of $12.84 billion, a price-to-earnings ratio of 16.98, a PEG ratio of 1.08 and a beta of 0.38. The business has a 50 day simple moving average of $44.13 and a two-hundred day simple moving average of $43.44. </p><ul><li>3 Stocks to Buy for a Soft Landing, If There Is One</li></ul><p>Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.12. The firm had revenue of $610.81 million during the quarter, compared to the consensus estimate of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company's quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.55 EPS.  Sell-side analysts anticipate that  Exelixis, Inc. will post 3.15 EPS for the current fiscal year. </p><h2>Insider Activity</h2><p>In related news, EVP Patrick J. Haley sold 67,814 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the sale, the executive vice president owned 381,908 shares in the company, valued at approximately $16,620,636.16. This represents a 15.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Christopher J. Senner sold 30,617 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total value of $1,337,044.39. Following the sale, the chief financial officer owned 976,092 shares in the company, valued at $42,625,937.64. The trade was a 3.04% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 382,811 shares of company stock worth $17,014,813. 2.60% of the stock is owned by corporate insiders. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li></ul><p>A number of equities analysts have weighed in on the company. Royal Bank Of Canada decreased their target price on Exelixis from $46.00 to $43.00 and set a &#34;sector perform&#34; rating for the company in a research report on Monday, March 2nd. Morgan Stanley boosted their target price on Exelixis from $49.00 to $50.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, May 6th. Stifel Nicolaus boosted their price target on Exelixis from $44.00 to $47.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, May 6th. TD Cowen boosted their price target on Exelixis from $51.00 to $55.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, May 6th. Finally, Truist Financial upgraded Exelixis to a &#34;strong-buy&#34; rating in a research note on Monday, April 27th. One analyst  has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued  a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and an average price target of $47.35.</p><p><b>Get Our Latest Research Report on Exelixis</b></p><h2>Exelixis Profile</h2> (Free Report)<p>Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.  </p><p>The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Exelixis</li><li>YETI Rallies After Earnings Beat and Raised Outlook</li><li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li><li>Cisco’s Vertical Rally May Still Be in the Early Innings</li><li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li></ul><p><strong>Want to see what other hedge funds are holding EXEL?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Exelixis Right Now?</h2><p>Before you consider Exelixis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p><p>While Exelixis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

EXEL

<p>Ameritas Advisory Services LLC acquired 34,270 shares of Exelixis, Inc. (NASDAQ:EXEL) valued at approximately $1.5 million during Q4. Other hedge funds also increased their positions in the company. Exelixis reported solid earnings, with a quarterly revenue of $610.81 million and an EPS of $0.87, surpassing estimates. Analysts have mixed ratings and target prices for the stock, reflecting varied outlooks on its performance.</p>

Market Beat

Exelixis

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

VG Health

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares US Pharma

Allianz

Allianz SE

UBS Group AG

ROYAL BANK OF CANADA

Morgan Stanley

Stifel Financial

Toronto Dominion Bank

Truist Financial

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Ameritas Advisory Services LLC Purchases Shares of 34,270 Exelixis, Inc. $EXEL